Karoń Przemysław, Olejek Anita, Olszak-Wasik Katarzyna
Ginekol Pol. 2014 Nov;85(11):847-51. doi: 10.17772/gp/1912.
Vulvar cancer accounts for about 3-5% of all female genital carcinomas. TGF-P protein is a member of a superfamily of cytokines that regulate cell functions. A correlation between this protein and many neoplastic processes was reported.
In our study we analyzed TGF-β expression in vulvar tumor among patients with diagnosed squamous cell carcinoma (with and without inguinal nodes metastases).
Paraffin embedded blocks obtained from vulvar tissues and inguinal nodes (from 31 patients with vulvar carcinoma FIGO ll-IV) were prepared. Next, the hematoxylin and eosin staining was performed. Monoclonal antibody NCL-TGF-beta was used for immunohistochemical tests.
Higher expression of TGF-beta in cancer cells corresponds to more advanced cancer stages (FIGO). A positive correlation between TGF-beta and metastases, as well as a number of inguinal nodes metastases was observed. The ratio between the number of stained cells in vulvar tumor and of inflammatory cells proved to be higher in FIGO stage III than IV Possibly TGF-beta increase in vulvar tumor contributes to the breakdown of immunological processes limiting cancer progression. Higher TGF-beta expression leads to metastasis in regional lymphatic nodes.
TGF-beta overproduction is observed in vulvar neoplastic processes. In early stages of carcinogenesis TGF-beta inhibits cancer cell proliferation, but in more advanced stages it accelerates cancer progression by inhibiting the immunological response.
外阴癌约占所有女性生殖系统癌的3 - 5%。转化生长因子-β(TGF-β)蛋白是调节细胞功能的细胞因子超家族的成员。据报道该蛋白与许多肿瘤形成过程之间存在关联。
在我们的研究中,我们分析了确诊为鳞状细胞癌(有或无腹股沟淋巴结转移)的患者外阴肿瘤中TGF-β的表达情况。
制备从外阴组织和腹股沟淋巴结(来自31例FIGO II - IV期外阴癌患者)获取的石蜡包埋块。接下来,进行苏木精和伊红染色。单克隆抗体NCL - TGF - beta用于免疫组织化学检测。
癌细胞中TGF - beta的高表达对应于更晚期的癌症阶段(FIGO分期)。观察到TGF - beta与转移以及腹股沟淋巴结转移数量之间存在正相关。FIGO III期外阴肿瘤中染色细胞数量与炎症细胞数量之比高于IV期。可能外阴肿瘤中TGF - beta的增加导致了限制癌症进展的免疫过程的破坏。较高的TGF - beta表达导致区域淋巴结转移。
在外阴肿瘤形成过程中观察到TGF - beta过度产生。在致癌作用的早期阶段,TGF - beta抑制癌细胞增殖,但在更晚期阶段,它通过抑制免疫反应加速癌症进展。